SARS-CoV-2 Vaccination in Androgen Sensitive Phenotypes – A Study on Associated Factors for SARS-CoV-2 Vaccination and Its Adverse Effects Among Androgenetic Alopecia and Benign Prostate Hyperplasia Patients

September 2022 in “ Frontiers in Immunology ”

Zhihua Fan, Shixin Duan, Fangfen Liu, Wei Shi, Ziye Yang, Rui-Yang Bai, Tao Li, Jingxian Chen, Hongfu Xie, Ji Li, Yan Tang

androgenetic alopecia benign prostatic hyperplasia anti-androgen therapy SARS-CoV-2 vaccination injection site pain SARS-CoV-2 specific IgG levels AGA BPH COVID-19 vaccine

Studysummary This study reports that comorbidities and anti-androgen therapy were associated with lower SARS-CoV-2 vaccination rates among patients with androgenetic alopecia, emphasizing the need to promote vaccination within this group.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on frontiersin.org →

Discuss this study in the Community →

Research cited in this study

9 / 9 results

Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

research Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

42 citations , July 2021 in “Frontiers in Medicine”

In this study, proxalutamide significantly reduced the 30-day hospitalization rate by 91% compared to placebo in men with COVID-19 treated in outpatient settings.

Is COVID-19 a Risk Factor for Progression of Benign Prostatic Hyperplasia and Exacerbation of Its Related Symptoms?: A Systematic Review

research Is COVID-19 a Risk Factor for Progression of Benign Prostatic Hyperplasia and Exacerbation of Its Related Symptoms?: A Systematic Review

21 citations , May 2021 in “Prostate Cancer and Prostatic Diseases”

This review analyzes the potential mechanisms by which SARS-CoV-2 may exacerbate symptoms of benign prostatic hyperplasia and suggests a connection via ACE2 and androgen receptor pathways; it reports no new clinical results.

Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial

research Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial

41 citations , February 2021 in “Cureus”

This study found that in males with mild COVID-19, treatment with dutasteride, along with standard therapy, may reduce viral shedding and inflammation compared to placebo.

research Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men

139 citations , December 2020 in “Cell Stem Cell”

Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.

Androgenetic Alopecia May Be Associated With Weaker COVID-19 T-Cell Immune Response: An Insight Into a Potential COVID-19 Vaccine Booster

research Androgenetic Alopecia May Be Associated With Weaker COVID-19 T-Cell Immune Response: An Insight Into a Potential COVID-19 Vaccine Booster

9 citations , November 2020 in “Medical Hypotheses”

Hair loss may link to weaker COVID-19 immunity, suggesting possible need for extra vaccine boost.

research Sex Differences in COVID-19: The Role of Androgens in Disease Severity and Progression

121 citations , November 2020 in “Endocrine”

This review discusses evidence on androgen sensitivity as a potential factor in COVID-19 disease severity, suggesting that androgen receptor interactions could influence virus entry and progression, and reports no new clinical results.

research 5-Alpha-Reductase Inhibitors Are Associated With Reduced Frequency of COVID-19 Symptoms in Males With Androgenetic Alopecia

36 citations , November 2020 in “Journal of The European Academy of Dermatology and Venereology”

This study found that 5-alpha-reductase inhibitors were associated with a reduced frequency of COVID-19 symptoms in males with androgenetic alopecia.

research Androgenetic Alopecia Present in the Majority of Patients Hospitalized with COVID-19: The 'Gabrin Sign'

119 citations , May 2020 in “Journal of The American Academy of Dermatology”

This study observed a high prevalence of androgenetic alopecia in patients hospitalized with severe COVID-19, with 79% of men and 42% of women affected, suggesting a potential link between androgen sensitivity and COVID-19 severity.

research Guidelines for the Diagnosis and Treatment of Male-Pattern and Female-Pattern Hair Loss, 2017 Version

36 citations , June 2018 in “Journal of Dermatology”

This article updates Japanese guidelines for diagnosing and treating male and female-pattern hair loss, recommending specific drugs and therapies while advising against certain treatments for female-pattern hair loss.